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ABSTRACT
Objectives: The goal of comparative effectiveness analysis is to examine
the relationship between two variables, treatment, or exposure and effec-
tiveness or outcome. Unlike data obtained through randomized controlled
trials, researchers face greater challenges with causal inference with obser-
vational studies. Recognizing these challenges, a task force was formed to
develop a guidance document on methodological approaches to addresses
these biases.
Methods: The task force was commissioned and a Chair was selected by
the International Society for Pharmacoeconomics and Outcomes Research
Board of Directors in October 2007. This report, the second of three
reported in this issue of the Journal, discusses the inherent biases when
using secondary data sources for comparative effectiveness analysis and
provides methodological recommendations to help mitigate these biases.
Results: The task force report provides recommendations and tools for
researchers to mitigate threats to validity from bias and confounding in
measurement of exposure and outcome. Recommendations on design of
study included: the need for data analysis plan with causal diagrams;
detailed attention to classiﬁcation bias in deﬁnition of exposure and clini-
cal outcome; careful and appropriate use of restriction; extreme care to
identify and control for confounding factors, including time-dependent
confounding.
Conclusions: Design of nonrandomized studies of comparative effective-
ness face several daunting issues, including measurement of exposure and
outcome challenged by misclassiﬁcation and confounding. Use of causal
diagrams and restriction are two techniques that can improve the theo-
retical basis for analyzing treatment effects in study populations of more
homogeneity, with reduced loss of generalizability.
Keywords: comparative effectiveness, epidemiology, nonrandomized
studies, research design, secondary databases.
Background to theTask Force
In September 2007, the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) Health Science Policy
Council recommended that the issue of establishing a task force
to recommend Good Research Practices for Designing and Ana-
lyzing Retrospective Databases be considered by the ISPOR
Board of Directors. The Council’s recommendations concerning
this new task force were to keep an overarching view toward the
need to ensure internal validity and improve causal inference
from observational studies, review prior work from past and
ongoing ISPOR task forces and other initiatives to establish
baseline standards from which to set an agenda for work. The
ISPOR Board of Directors approved the creation of the task force
in October 2007. Task force leadership and reviewer groups were
ﬁnalized by December 2007 and the ﬁrst teleconference took
place in January 2008.
The task force members were experienced in medicine, epi-
demiology, biostatistics, public health, health economics, and
pharmacy sciences, and were drawn from industry, academia and
as advisors to governments. The members came from the UK,
Germany, Austria, Canada, and the United States.
Beginning in January 2008, the task force conducted monthly
teleconferences to develop core assumptions and an outline
before preparing a draft report. A face-to-face meeting took place
in October 2008, to develop the draft and three forums took
place at the ISPOR meetings to develop consensus for the ﬁnal
draft reports. The draft reports were posted on the ISPOR
website in May 2009 and the task forces’ reviewer group and
ISPOR general membership were invited to submit their com-
ments for a 2-week reviewer period. In total, 38 responses were
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received. All comments received were posted to the ISPOR
website and presented for discussion at the task force forum
during the ISPOR 12th Annual International Meeting in May
2009. Comments and feedback from the forum and reviewer and
membership responses were considered and acknowledged in the
ﬁnal reports. Once consensus was reached, the article was sub-
mitted to Value in Health.
Introduction
The goal of comparative effectiveness analysis is to examine the
relationship between two variables, treatment or exposure, and
effectiveness or outcome. The advantages of using secondary
databases to examine this relationship are easily recognized by
researchers in the ﬁeld. Compared with data obtained through
randomized controlled trials (RCTs), secondary data sources
provide a low-cost means of answering the research question,
answers can be obtained in a relatively short time frame, the data
are more representative of routine clinical care and large cohorts
of patients can be followed over long time periods [1]. However,
researchers should be mindful of data limitations that, in some
instances, preclude their use. In this section, we will address
issues of validity with respect to secondary data sources and,
where appropriate, provide researchers with tools to help miti-
gate threats to validity.
Researchers have been writing about the challenges that sec-
ondary data sources pose for more than two decades now [2–4],
and although challenges still exist, themethodological approaches
to address these challenges have greatly improved [5,6]. Key in
contributing toward inaccuracies in administrative data is the fact
that they were built for billing and record keeping purposes, not
for research. Therefore, the potential for error occurs at many
points along the record keeping process [7]. The implication for
researchers is that both systematic and random error can occur in
the identiﬁcation of treatment exposure and outcome.
In RCTs, identifying and measuring exposure is done with a
great deal of accuracy and precision. For example, in a clinical
trial evaluation of drug treatment, not only is it known who has
received the active drug, but also the degree of exposure—dose,
duration and compliance with therapy. Similarly, outcomes—or
measures of effectiveness—are measured with a great deal of
accuracy and precision. Various devices and laboratory tests are
used to measure and record both surrogate (blood pressure,
cholesterol levels, tumor staging) and ﬁnal end points (e.g., myo-
cardial infarction [MI], stroke, and even death). This same level
of precision is often not universally available in secondary data
sources. Additionally, secondary data limit the measure of expo-
sure and outcomes to those who seek care and is limited further
in administrative claims data to those who obtain this care
through the insurance payment system.
One way to measure the validity of exposure and outcomes
using administrative data is to compare it with the gold standard.
For outcome measures that gold standard is often patient self-
report or the medical record. When using the gold standard of
medical records, the sensitivity and speciﬁcity of medical claims
data were found to have a high level of speciﬁcity but a great deal
of variability in sensitivity across diagnoses [8]. For drug expo-
sure, there have been indirect assessments of accuracy of pre-
scription claims by comparing drug compliance metrics using
pharmacy claims data with other compliance measures including
patient self-report [9,10] and studies testing the accuracy of
prescription claims information to deﬁne or supplement case
deﬁnitions for hypertension [11]. Direct assessments of the valid-
ity of prescription claims comparing prescription claims with
other medical data, such as a patients chart, have generally been
performed in narrow populations or for selected drug classes and
the results have been highly variable [4,12–15]. Although pre-
scription claims are generally considered a valid measure of drug
exposure, inaccuracies in measurement still exist.
Measurement of Exposure and Outcome
This paper ﬁrst addresses how exposure and outcomes are mea-
sured using secondary data sources, discuss instances of misclas-
siﬁcation and ways to mitigate these biases. This is followed by a
discussion on confounding in epidemiological research and meth-
odological approaches researchers should consider to control for
confounding.
Measurement—Exposure
Secondary data sources measure drug exposure with varying
degrees of accuracy. Table 1 highlights these data sources, the
level of measurement, and inherent limitations in using these data
sources for drug exposure.
Considered the most accurate and most commonly used
measure of drug exposure is outpatient prescription claims. Pre-
scription claims data provide a wealth of information on drug
exposure including date of service, dispensing pharmacy, drug
name, quantity, dose, and duration (days supply), and are con-
sidered by many to be the gold standard for measuring drug
exposure [16]. It should be noted that days’ supply can be unre-
liable for some drug classes (i.e., injectables or medications dosed
on an as needed basis) and outside the United States, measures of
duration may not be available.
Several options are available to identify drugs from outpa-
tient prescription claims ﬁles. First is the National Drug Code
(NDC), a 10-digit coding system established by the Food and
Drug Administration (FDA) to uniquely identify drug, dosage,
and package size. The FDA provides a complete listing of NDCs
on its website however the drug lists can become cumbersome to
manage, are time sensitive—changing with new drug entries or
exits from the market. They can also be quite cumbersome to
code particularly when a large number of NDCs codes are used.
For example, using only the ﬁrst nine digits of the NDC, which
ignores package size, there are over 280 NDCs for the beta-
Table 1 Secondary data sources and measurement of drug exposure
Data source Measurement Type of exposure measured Limitations
Outpatient prescription
claims
NDC or therapeutic classiﬁcation
system (i.e., GCN,ATC,AHFS, etc.)
Incidence and prevalence use and intensity
of exposure
See expanded discussion on misclassiﬁcation
Medical records/charts Drug name, dosage and regimen for
prescribed and OTC agents
Binary drug exposure (incidence/prevalence) Incomplete capture of patients’ medication




Health Care Procedure Codes only
for select medications
Binary drug exposure (incidence/prevalence)
and persistency
Limited to only those medications
administered in the physician’s ofﬁce
AHFS,American Hospital Formulary Service;ATC,Anatomical Therapeutic Chemical; GCN, generic code number.
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blocker Atenolol. To simplify drug identiﬁcation, researchers can
purchase a therapeutic classiﬁcation system such as the American
Hospital Formulary Service Pharmacologic-Therapeutic Classiﬁ-
cation, Red Book, Anatomical Therapeutic Chemical classiﬁca-
tion system or Medi-Span’s Generic Product Identiﬁer. These
systems link NDC to drug classes, which allow for more man-
ageable coding of unique drugs or therapy class.
Medical records can be another data source to identify drug
exposure recording whether the physician prescribed medication
for the patient, the dose, and intended regimen. However,
medical records do not record whether the patient obtained the
medication from the pharmacy, or typically the degree of expo-
sure (i.e., compliance). Additionally, the medical record (either
inpatient or outpatient) does not record all prescribed medica-
tions taken by patients and is generally not considered a valid
source for identifying drug exposure. However, medical records
may be considered as a source for capturing over-the-counter
(OTC) agents, typically not covered or captured in the prescrip-
tion claim record. In the United States, it should be noted that the
FDA will not accept e-medical records as a source for measuring
drug exposure.
Drug exposure can also be measured using outpatient medical
claims for a limited number of medications dispensed and admin-
istered in the physicians’ ofﬁce. In the United States, these are
captured using Health Care Procedure Codes (HCPCS). However,
drug use identiﬁed from HCPCS codes do not indicate dosage and
are not immediately assigned to newer agents. Additionally,
medical billers often use miscellaneous J-codes when billing for
medications administered in physician ofﬁces, which does not
allow for accurate identiﬁcation of the drug administered.
Another challenge faced by researchers in measuring expo-
sure is accounting for switching in the assignment to exposure
groups. Switching from one drug therapy to another often occurs
naturally as a result of treatment failure or systematically from
changes in beneﬁt design [17] or programmatic features such as
formulary status changes. Researchers should establish criteria
a priori for treatment group assignment, be transparent in
methods, and conduct sensitivity analysis to determine the
impact of treatment identiﬁcation on study results.
Measurement—Outcomes
For a given disease or condition, various measures of clinical
effectiveness exist. For example, in the treatment of high choles-
terol, measures of clinical effectiveness include both intermediate
measures, such as the biomarker low-density lipoprotein choles-
terol and cardiovascular end points including stroke or MI.
Outside of the RCT environment, researchers face limitations in
measuring effectiveness, particularly those that involve interme-
diate biomarkers or self-reported symptom scales and measures
of patient functioning. Among secondary data sources, medical
records are typically considered the gold standard for capturing
intermediate and ﬁnal outcomes (Table 2). Other secondary data
sources, although providing a wealth of information on treat-
ment patterns and medical events are more limited in measuring
effectiveness. Administrative claims data can identify ﬁnal end
points such as fractures, stroke, or MI but are limited to proxy
measures at best in the measurement of intermediary outcomes.
Using a combination of diagnostic, procedure, or facility codes,
researchers are beginning to develop proxy measures of interme-
diate outcomes with some success. For example, a study exami-
ning disease severity for chronic obstructive pulmonary disease
used diagnostic and inpatient hospital stays to classify severe or
moderate COPD and found moderate accuracy to medical charts
[18].
There is growing use of laboratory results data linked to
administrative claims data to measure intermediate outcomes.
However, these data are as yet to be made available on a large
scale in the United States.
Classiﬁcation Bias
Systematic and random errors can occur in measuring both expo-
sure and outcome resulting in the violation of internal validity.
This error is termed classiﬁcation bias—identifying subjects as
being exposed to drug when they are not or not exposed when
they are. Classiﬁcation bias is further categorized as differential
or nondifferential and unidirectional or bidirectional. Nondiffer-
ential misclassiﬁcation occur when the likelihood of misclassiﬁ-
cation is the same across the exposed or outcome groups. For
example, exposure misclassiﬁcation for a low-cost medication
using prescription claims data would be equally likely regardless
of outcome. However, differential misclassiﬁcation is present
when the likelihood of misclassiﬁcation is different between
exposed or outcome groups. An example of differential misclas-
siﬁcation for drug exposure is when those who are exposed have
a lower likelihood of outcome misclassiﬁcation because to
receive medication they have to enter the health-care system,
which increases their likelihood of recording a diagnosis. Those
not exposed are much more likely to be misclassiﬁed as not
having the disease, which is an artifact of not entering the health
care system. Unidirectional misclassiﬁcation occurs when the
Table 2 Secondary data sources for measuring outcomes
Data source Measurement Outcome measured
Medical records Manual or automated (electronic medical records) extrapolation
of diagnoses, procedures and treatments, biomarkers and other
laboratory data
Used alone or with other data sources to identify disease
progression, surrogate, or ﬁnal end points
Outpatient medical claims ICD-9 or ICD-10-CM, OXMIS,This paper ﬁrst addresses how
exposure and outcomes are measured using secondary data
sources, discuss instances of misclassiﬁcation and ways to
mitigate these biases.This is followed by a discussion on
confounding in epidemiological research and methodological
approaches researchers should consider to control for
confounding, CPT-4, OPCS-4, laboratory testing, diagnostic tests
Used alone or with other data sources to identify disease
progression, surrogate or ﬁnal end points
Eligibility ﬁles Death*
Inpatient medical claims ICD-9 or ICD-10-CM, OXMIS,The Read Codes, CPT-4, OPCS-4,
laboratory testing, diagnostic tests, discharge status
Used alone or with other data sources to identify disease
progression, events or ﬁnal end points
*May not be documented as such in all cases.
ICD, International Classiﬁcation of Diseases;OXMIS,Oxford Medical Information System;CPT,current procedural terminology;OPCS-4,Ofﬁce of Population,Censuses and Surveys Classiﬁcation
of Operations and Surgical Procedures (4th revision).
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direction of the misclassiﬁcation is in the same direction. Bidi-
rectional misclassiﬁcation occurs when the likelihood of misclas-
siﬁcation is in both directions—there is a probability that cases
appear as controls and controls appear as cases. For a more
complete discussion see Hartzema and Perfetto [19]. As a
researcher, one should consider and state the direction of poten-
tial sources of misclassiﬁcation and how that could inﬂuence the
rejection of the null hypothesis [7].
An important data element inﬂuencing classiﬁcation bias of
both drug exposure and outcomes when using secondary data
sources is member eligibility. In the United States, many admin-
istrative datasets are linked to employment and natural transi-
tions in the labor market can inﬂuence classiﬁcation bias. If
eligibility is not accounted for in the measure of medication
compliance, for example, those not continuously eligible may be
incorrectly classiﬁed as noncompliant when in fact the lack of
drug exposure was caused by the loss of eligibility. Statistically
controlling for length of eligibility or limiting to continuously
eligible in these instances may be most appropriate. Lack of
appropriate time for follow-up because of drops in eligibility is
also a concern for outcomes misclassiﬁcation if member
follow-up does not allow for capture of the clinical event. Eligi-
bility must be controlled for and lack of this information pre-
cludes comparative effectiveness research.
Drug Exposure Misclassiﬁcation
Many factors can lead to misclassiﬁcation with respect to drug
exposure. With outpatient prescription claims, a greater number
of opportunities for misclassiﬁcation in the direction of not
exposed exist given the multiple channels by which members can
receive their medications outside of the reimbursement arrange-
ments of third-party payers. Other means for obtaining prescrip-
tion drugs that would preclude claims capture include physician
samples, patient assistance programs (PAP), paying out of
pocket, inpatient hospital stays, taking a medication belonging
to someone else, secondary insurance coverage, or fraudulent
behavior. The likelihood of this misclassiﬁcation can be inﬂu-
enced by patient demographics and plan design. For example, the
elderly and lower-income patients or those facing higher out-of-
pocket payments may be more likely to participate in PAP pro-
grams or obtain samples from their physician, leading to
systematic misclassiﬁcation.
Various trend and utilization management programs can also
lead to misclassiﬁcation. Programmatic features including prior
authorization policies, caps, or maximum limits on coverage, and
pharmaceutical step therapy programs can inﬂuence not only the
measure of exposure but assignment to exposure category. This
information, although not always readily available to research-
ers, would represent a major limitation if not documented. More
recently, the proliferation in the United States of no-cost or
low-cost generic programs offered by retail chain pharmacies are
increasing the likelihood of misclassiﬁcation since these claims
are not captured by the health plan. This could lead to bias
depending upon the drug comparators, study sample, or geo-
graphic region given that market penetration of these programs
differ by region.
Differences in formularies, or the list of covered drugs, can
lead to misclassiﬁcation. Systematic errors in exposure classiﬁ-
cation can occur when the treatments being compared have
different formulary status or are on different tiers. If drug A is a
second tier product being compared with drug B, which is a third
tier product where members pay a higher copayment, differential
classiﬁcation bias could result, assuming higher copayments lead
to lower compliance, which could impact outcomes. Methods to
address these issues are covered in later sections.
Additionally, for administrative claims data, classiﬁcation
bias is present when measuring exposure for OTC medications or
medications with limits or coverage exclusions (medications used
to treat cosmetic indications). For ambulatory comparative effec-
tiveness analysis, hospital stays (or other inpatient stays) must be
accounted for in the statistical analysis [20]. However, the
random bias that occurs when patients use other channels to
receive medication can only be addressed as a potential study
limitation.
The level of exposure misclassiﬁcation can also be inﬂuenced
by the study design. One important choice in the design of
database studies is the time-window during which patients are
considered “exposed.” This will impact misclassiﬁcation of not
only exposure but also outcome measurement. A study that is
based on prescription information can use, for example, a
3-month time-period following each prescription in order to
assess the outcome and estimate the risk of the outcome during
this time-period. Although this is not always recognized, the
choice of this exposure time-window is of major importance.
Since misclassiﬁcation of the relevant exposure time will lead to
a nondifferential bias toward the null. The choice of the exposure
time-window should not be based on the actual drug intake, but
rather on the time-period during which the medication may cause
the outcome and the duration of the pathogenic process [21,22].
As an example, a study of the effects of a medication on the
risk of malignancies may suffer from a major exposure misclas-
siﬁcation if the exposure time window would be based on the
time period of drug intake and the study would include many
short-term users. On the other hand, a study of allergic reactions
would also suffer from exposure misclassiﬁcation if the exposure
time window goes beyond what is considered clinically relevant.
Different approaches to improve the characterization of the
exposure time window include efforts to validate the relationship
or sensitivity analysis, repeating the analysis with different expo-
sure time windows.
The focus of exposure misclassiﬁcation has been in the direc-
tion of not exposed. However, it should be noted that the direc-
tion of misclassiﬁcation can also be toward exposure. It cannot
be assumed that presence of a claim indicates that the patient
actually took the medication. For example, patients may obtain
a medication for antibiotic or pain therapy, and take only if
symptoms appear increasing the likelihood for misclassiﬁcation
toward exposed.
Outcome Misclassiﬁcation
Several factors can lead to misclassiﬁcation of diagnostic or
procedure codes including plan payment systems, diagnoses, and
the speciﬁcity of coding in the database [1,7]. Reimbursement
systems based upon capitated payment arrangements where pro-
viders are less incentivized to submit claims documenting care
compared with fee for service payment arrangements are more
prone to classiﬁcation bias. Under capitated payment systems,
researchers should proceed with caution and attempt to validate
claims data with external data sources (i.e., medical chart
review).
Misclassiﬁcation has been shown to vary by disease state with
hypertension and diabetes having the highest rates of sensitivity
(60.6 and 62.6, respectively) and chronic liver disease, peptic
ulcer disease, or acute myocardial infarction with some of the
lowest levels of sensitivity (27.6, 27.6, and 25.4, respectively) [8].
This variability can be caused by multiple factors including clini-
cal ambiguity in diagnoses, stigma associated with the diagnoses
or coding used for rule out diagnostic procedures. Using a longer
look back period and requirements of at least two diagnoses or
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inclusion of medical treatment can increase speciﬁcity [23]. Also
being explored is the use of algorithms using drug, medical and
patient demographic information to increase the accuracy of
diagnostic information [24]. Systematic error in classiﬁcation of
outcomes can occur if the researcher fails to take into account
changes in codes resulting from updates or brought about by the
transition from the International Classiﬁcation of Diseases
(ICD)-9 to ICD-10 coding systems.
When considering various approaches, researchers should
seek out deﬁnitions that have been validated with external
sources, such as chart review. When there are several approaches
without a clear empirical direction, sensitivity analyses should be
explored to understand the implications of the various deﬁnitions
on the results. For example, MI may be deﬁned using two diag-
noses or one diagnosis and a hospital stay, which will alter the
incidence of MI detected in the study. When measuring comor-
bidity ideally one should select a measure that has been validated
in a population most similar to the study and for the outcome
under investigation.
Recommendations
1. State the direction of potential sources of misclassiﬁcation
and how that could inﬂuence the acceptance or rejection of
the null hypothesis.
2. Eligibility must be controlled for and lack of this informa-
tion precludes comparative effectiveness research.
3. For ambulatory comparative effectiveness analysis, hospital
stays (or other inpatient stays) must be accounted for in the
statistical analysis.
4. The choice of the exposure time-window should not be
based on the actual drug intake, but rather on the time-
period during which the medication may cause the outcome
and the duration of the pathogenic process.
5. Deﬁnitions that have been validated with external sources,
such as chart review, should be used as the primary method
in deﬁning the measure. When there are several approaches
without a clear empirical direction, sensitivity analyses
should be explored to understand the implications of the
various deﬁnitions on the results.
6. When measuring comorbidity, select a measure that has
been validated in a population most similar to the study and
for the outcome under investigation.
Confounding and Causal Graphs
Issues surrounding misclassiﬁcation is not the only bias that
researchers are faced with when using retrospective secondary
data sources. Confounding also comes into play. Confounding is
classically deﬁned as a bias that distorts the exposure-disease or
exposure-outcome relationship [25]. Frequently used deﬁnitions
of confounding and standard textbook methods to control for
confounding state that a confounder is an independent (causal)
risk factor for the outcome of interest that is associated with the
exposure of interest in the population, but that is not an inter-
mediate step in the causal pathway between the exposure and the
outcome [26,27].
Confounding by Indication for Treatment
A common and pernicious problem endemic to pharmacoepide-
miologic studies is confounding by indication of treatment. For
example, when the choice of therapy is affected by the severity of
illness, and physicians prescribe one therapy over another
depending on the severity and the perceived effectiveness of one
drug compared with another for patients with differing severity
levels, then confounding by indication for treatment occurs
(assuming that the severity of disease also is a risk factor for the
outcome of interest). In this case, apparent (i.e., estimated) treat-
ment effects are confounded, that is, they are not causal but they
may actually be caused by the severity of illness that led to
patients being prescribed a given treatment.
Measured versus Unmeasured Confounding
Confounders may be measured or unmeasured. Secondary data-
bases of a variety of sources may contain a wide and rich variety
of information that can be used to measure an array of poten-
tially confounding factors. However, even the most detailed and
complete data sources may fail to include information on poten-
tial confounding factors, and these remain unmeasured and
hence uncontrolled in a given study leading to residual confound-
ing. Methods to address both measured and unmeasured
(residual) confounding factors have been developed to address
these concerns and will be detailed in the third series of the task
force’s report.
Time-Dependent Confounding
The more complicated (but probably not less common) case of
time-dependent confounding refers to variables that simulta-
neously act as confounders and intermediate steps, that is, con-
founders and risk factors of interest mutually affect each other.
Confounding by indication, may take the form of time dependent
confounding. An example is the effect of aspirin use (treatment)
on risk of MI and cardiac death (outcome). Prior MI is a con-
founder for the effect of aspirin use on risk of cardiac death,
because prior MI is a cause of (subsequent) aspirin use, and is
also a causal risk factor for (subsequent) cardiac death. However,
(prior) aspirin use also causally prevents prior MI. Therefore,
prior MI simultaneously acts as confounder (causing aspirin use)
and intermediate step (being affected by aspirin use), and hence is
a time-dependent confounder affected by previous treatment.
Traditional textbook techniques to control for time-
independent confounding include restriction, stratiﬁcation,
matching, or multivariate regression analysis. However, these
methods have been criticized for being inadequate to control
for time-dependent confounding. Other methods such as
g-computation, marginal structural models, or structural nested
models have been suggested as approaches to this problem
[28,29].
These analytic methods require repeated measurements of the
treatment of interest, potential confounders and the outcome.
With the proliferation of longitudinal data sources, where
patients are followed up over years of exposure to medical thera-
pies, these analytic methods should be applied.
Causal Graphs
To address the issue of confounding in retrospective databases
and to be able to do a proper causal analysis, we must answer
three questions: 1) which a priori assumptions can we make
about the causal relationships between the variables of an epide-
miological study?; 2) under these assumptions, are the observed
data sufﬁcient to control for confounding?; and 3) what methods
are appropriate to control for confounding?
Causal graphs can guide us in answering these questions [30].
Directed acyclic graphs (DAGs) are causal graphs that can be
used to understand and explicitly state causal a priori assump-
tions about the underlying biological mechanisms [31,32]. DAGs
consist of a set of nodes and directed links (arrows) that connect
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certain pairs of nodes (see Fig. 1). For our purposes, nodes rep-
resent variables and arrows denote causal relationships. A set of
precise graphical rules for DAGs has been developed, which
allows us to determine whether an unbiased effect is estimable
from the observed data, which variables must be adjusted for in
the analysis, and which statistical methods can be used to obtain
unbiased causal effects. Part of these rules is a new and graphi-
cally oriented deﬁnition of confounding (i.e., the “backdoor
criterion”).
Furthermore, DAGs offer a readily accessible approach to
understanding complex statistical issues including the fallibility
of estimating direct effects (i.e., controlling for intermediate
steps), the rationale for instrumental variables, and controlling
for compliance in randomized clinical trials (when both
“intention-to-treat” [ITT] and “per protocol” analyses can fail to
yield the true causal intervention effect). In conclusion, DAGs are
a valuable and comprehensive tool that offers epidemiologists
and outcomes researchers better insight into confounding and the
causal interpretation of their model results.
Another example of time-dependent confounding by treat-
ment is antiviral treatment of HIV infection, where treatment or
dose may depend on CD4-count and this dependency may con-
tinue over the course of the disease [33].
In the conduct of nonrandomized comparative effective-
ness studies, it is strongly recommended to: 1) deﬁne the DAG
for the base-case analysis before actually starting the analysis;
2) report the DAG for the base-case analysis; and 3) if sensi-
tivity analyses are performed for different assumptions regard-
ing the confounding structure, to report the additional DAGs
representing the assumptions of the respective sensitivity
analyses.
One additional approach for assessing the likelihood that
residual confounding may be responsible for an observed treat-
ment effect would be to conduct a sensitivity analysis exploring
the effect of the treatments on outcomes that should not be
inﬂuenced by the treatment in addition to the primary end points.
For example, in an analysis to compare different prostate cancer
treatments, one could explore recurrent cancer related mortality
or all cause mortality as primary end points and additionally
compare the treatments on outcomes unrelated to the disease or
the treatments such as pulmonary or diabetes-related mortality. If
a prostate cancer treatment was found to have a beneﬁcial effect
on cancer mortality but no impact on diabetes related mortality,
there is greater conﬁdence linking the treatment to the primary
end point, however, if a beneﬁcial effect is also found for diabetes
mortality, it is less clear if the treatments are inﬂuencing the
primary cancer beneﬁt or if the therapy is more likely to be
prescribed for “healthier” patients that could not be controlled in
the analysis [34].
Recommendations:
1. Deﬁne the DAG for the base-case analysis before actually
starting the analysis.
2. Report the DAG for the base-case analysis.
3. If sensitivity analyses are performed for different assump-
tions regarding the confounding structure, report the addi-
tional DAGs representing the assumptions of the respective
sensitivity analyses
Restriction—Inclusion and Exclusion Criteria
Although a variety of systematic errors may bias nonexperimen-
tal research [35] confounding bias is of particular concern in
epidemiologic studies of drug effects [36].
Restricting study cohorts to patients who are homogeneous
regarding their indication for the study drug will lead to more
balance of patient predictors of the study outcome among expo-
sure groups and thus will reduce confounding but not necessarily
eliminate confounding, particularly when there are variables that
inﬂuence prescribing decisions that are not available in the data.
Restricting study cohorts can also increase the likelihood that all
included subjects will have a similar response to therapy and
therefore reduce the likelihood of effect modiﬁcation. RCTs com-
monly restrict their study population to patients with a presumed
indication for the study drug and then randomly allocate the
actual treatment.
There are many different approaches to restriction in speciﬁc
studies [37] and it is therefore difﬁcult to provide generic advice
that ﬁts speciﬁc study designs. However, several guiding prin-
ciples can be identiﬁed that should be considered in a nonran-
domized database study on effectiveness and safety of medical
interventions [38].
Exclude Patients with a History of the Study Outcome?
The decision whether to exclude patients with a history of the
study outcome is largely based on the study questions and the
chronicity of the outcome under study. Some guiding principles
may include:
1. Patients with a history of occasionally or frequently occur-
ring events that are restored to a normal health level with or
without treatment may not be candidates for exclusion if
their health status has reached a normal level before cohort
entry. Examples for such conditions are uncomplicated viral
or bacterial infections.
2. Patients with a history of conditions that are markers for an
underlying chronic condition will have an increased risk for
the study outcome and at the same time may be more likely
to take a study medication causing confounding. Examples
for such conditions include hip fractures in elderly patients,
which are markers for frail health and/or osteoporosis,
which put the patient at increased risk for a future event.
Similarly, a previous MI is a strong risk factor for future
cardiac events. If these conditions are strong risk factors for
future events and therefore potentially strong confounders
it may be better to exclude these patients from the analysis
rather than adjusting for them.
Study Incident Medication Users Only?
Usually, an epidemiologic database study is implemented by
deﬁning a study period for which subjects are considered. Let us
Figure 1 Simple directed acyclic graph showing (a) time-independent and (b)
time-dependent confounding.
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consider a cohort study of statin use and some health outcome.
The most basic cohort deﬁnition would be to identify subjects
who used a statin at any point during the study period, assigning
the date of ﬁrst observed statin use during that period as an index
date. On each statin user’s index date, we sampled a subject who
had not used a statin as of that date, i.e., a nonuser, and assigned
him or her the same index date.
The population of statin users described earlier consists of a
mix of incident drug users, i.e., those starting on a statin, and
prevalent users, i.e., those taking a statin for some time.
Mixed Prevalent and Incident User Cohorts
Studying mixed prevalent and incident user cohorts will lead to
under-ascertainment of early events. Depending on the average
duration (chronicity) of use, such cohorts may be composed
predominantly of prevalent users and few new users (e.g.,
statins). The estimated average treatment effect will therefore
underemphasize effects related to drug initiation and will over-
emphasize effects of long-term use [39].
Prevalent users of a drug have by deﬁnition persisted in their
drug use, similar to the concept of survivor cohorts in chronic
disease epidemiology [40]. Being persistent or adherent is a char-
acteristic found more frequently in patients who tolerate the drug
well and who perceive some therapeutic beneﬁt. Adherence also
characterizes patients with higher educational status and health-
seeking behavior particularly if the study drug is treating an
asymptomatic condition like statins treating hyperlipidemia,
characteristics that are difﬁcult to assess in claims data, and may
lead to healthy user bias [41–43].
The duration of use among prevalent users can differ by
drug exposure; duration thus may cause bias if it remains unad-
justed. Such a scenario is likely when newly marketed drugs are
compared with competitors that have been available longer. In
database studies, duration of prior use can only be assessed by
tracing back a continuous string of prescriptions to the initial
prescription.
In studying prevalent users, investigators can assess patient
characteristics only after the initial exposure; thus the drug under
study may affect those characteristics. Adjusting for such factors
that are on the causal pathway of the drug’s action will lead to an
underestimation of the drug effects.
“New User Design.” One begins an incident user design by
identifying all patients in a deﬁned population who start a course
of treatment with the study medication. Exposed person-time
begins at the start of treatment, which is identiﬁed as a dispensing
of the index drugwithout a dispensing of the index drug during the
prior year or some other ﬁxed time interval comparable with a
wash-out period commonly used in RCTs. The advantage of the
so-called “New User Design” has recently been summarized [40].
Although limiting the study population to drug initiators
resembles one of several key characteristics of clinical trials, the
limited number of incident users requires large source populations
like health care utilization databases from which new starters can
be identiﬁed efﬁciently. For some patients it may not be the ﬁrst
time they take the study drug, i.e., they are not really naïve to the
drug. Patients who know from earlier treatment courses that they
tolerate the drug and that it is effective for them are more likely to
use the same drug again. The chance of an initiator to be a true new
user can be increased by requiring longer periods without use of
the study drug before the index prescription.
What Is the Most Adequate Comparison Group?
Choosing a comparison group is a complex and sometimes sub-
jective issue. The ideal comparison should comprise patients with
identical distributions of measured and unmeasured risk factors
of the study outcome.
Patients with the same treatment indication: “Alternative Drug
Users.” Selecting comparison drugs that have the same perceived
medical indication for head-to-head comparisons of active drugs
will reduce confounding by selecting patients with the same
indication (e.g., indication for using celecoxib vs. rofecoxib).
Although one can rarely measure the indication directly—in the
statin example we would need laboratory values of serum lipid
levels that are not routinely available in claims data—we infer the
indication by the initiation of a treatment speciﬁc to the indica-
tion. When studying unintended beneﬁts or risks of drugs, such
as exploring the potential cancer preventive properties of non-
steroidal anti-inﬂammatory drugs (NSAIDs), confounding by
indication may be less problematic as physicians are unlikely to
prescribe therapies based on a patient’s risk of developing the
un-intended outcome (e.g., cancer) assuming the disease(s) for
which the therapy are indicated are unrelated to the outcome.
However, new competitors within a class are often marketed for
better efﬁcacy, slightly expanded indications, or better safety
(cyclo-oxygenase-2 inhibitors [coxibs] vs. nonselective NSAIDs)
inﬂuencing physicians’ prescribing decisions [44]. In this way,
new opportunities of confounding by indication can arise.
“Nonusers.” In some cases there either is no comparator drug
with a reasonably close indication to the study drug or a class
effect is suspected such that the entire class is to be tested,
requiring comparison subjects who did not use any drug of this
class. The most obvious choice may be to identify study subjects
who do not use the study drug and then to pick a random date as
the index date, possibly matched by time to the index date of the
ﬁrst prescription among active drug users.
Obviously, patients on therapy most likely have a medical
indication; by contrast a large proportion of nonusers have no
medical indication, i.e., patients initiating statin therapy are more
likely to have elevated lipid levels and therefore increased cardiac
risks. However, nonusers as deﬁned earlier may differ substan-
tially from users of the index drug for both measured and unmea-
sured characteristics, even beyond the indication for the index
drug.
As a case in point: Although initiators of a new drug have
(presumably) been evaluated by a physician just before that
prescription, nonusers may not have seen a physician for a while
and, in fact, may have less contact with the health care system in
general. Differential underrecording of health conditions in the
nonuser comparison group makes members of the comparison
group appear healthier than they really are and may lead to an
overestimation of treatment effects.
Groups will be more comparable regarding access to health
care, including health-seeking behavior and disease surveillance,
when choosing comparison patients who also had contact with
the health-care system in the form of a drug dispensing. Like
patients starting the study drug, such patients have just been
evaluated by a physician before the initial prescription. Adequate
comparison groups for new statin initiators could, for example,
be initiators of topical glaucoma drugs or thyroid hormone sub-
stitution. Both these classes of pharmaceuticals are unrelated to
lowering serum lipid levels and are used for preventing the pro-
gression of an initially asymptomatic condition.
Excluding Patients with Contraindications?
In studies of the effectiveness of drugs it is questionable whether
we want to include patients who have a clear contraindication to
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the study drug. Such patients will be few and their experience will
be unusual. Prudence dictates, therefore, excluding patients with
contraindications or absolute indications, resulting in a situation
similar to the therapeutic equipoise required for RCTs [45].
Because reliably identifying contraindications in claims data
is unlikely, identifying them empirically is more promising. Pro-
pensity scores, a common mechanism for doing this, estimate
each patient’s probability of treatment given all measured cova-
riates. These propensity scores follow a distribution between 0
and 1 that differ between actual users and nonusers. On the low
end of the propensity score distributions indicating a low pro-
pensity for receiving treatment, there will be a range that is only
populated by actual nonusers because all users have a higher
propensity scores. Such nonusers are likely to have a contraindi-
cation for the study medication because no subject with such a
low propensity score has actually received treatment. These
patients should be deleted from the study population. Analo-
gously, such trimming can be considered at the upper end of the
propensity score, excluding patients who will always be treated.
Excluding Patients with Very Low Adherence?
Patients dropping out of RCTs for reasons related to the study
drug may cause bias. Noninformative dropout causes bias
towards the null in ITT analyses. The medical profession and
regulatory agencies accept such a bias because its direction is
known and trial results are considered conservative regarding the
drug’s effectiveness. Discontinuation of treatment may also be
associated with study outcomes. Obvious reasons are lack of
perceived treatment effect or intolerance. Both factors may lead
to early stopping but can cause discontinuation at any time later
during the course of treatment. Another factor that may lead to
discontinuation of medications, particularly those used to treat
asymptomatic conditions, is overall frail health status that
requires multiple medications to treat the more symptomatic
conditions. For example, cancer patients may discontinue statins
in order to reduce polypharmacy in favor of more urgently
needed drugs [42].
RCTs try to minimize bias from nonadherence by frequently
reminding patients and by run-in phases before randomization
aimed to identify and exclude nonadherent patients. In routine
care, adherence to drugs is unfortunately substantially lower
than in RCTs. Studies have shown, that for statin medications,
only 50% to 60% of elderly patients reﬁll their prescriptions
after 6 months [46].
Starting follow-up after the third ﬁll of a chronic medication
will exclude patients who are least adherent. Unlike RCTs in
which run-in phases are often done with placebo [47] patients in
routine care experience their ﬁrst exposure to a new drug and
may discontinue use because of a lack of effectiveness or intol-
erance during what may be the most vulnerable period for some
medication-outcome relations. As long as that proportion is
small and most patients discontinue for reasons not directly
related to the study drug(s), this issue should be minor.
Generalizability
To guide our thinking about generalizability, it is useful to specify
the patient to whom we wish to generalize our results. From a
patient and physician perspective, the most relevant and fre-
quently asked question is, “What is the effectiveness and safety of
a particular drug that I am about to start and continue to use,
compared with not starting therapy, or compared with starting
an alternative drug?” From this viewpoint, restricting studies to
initiators of drug therapy does not limit generalizability. Instead,
it avoids under-representation of treatment effects that occur
shortly after initiation. Patients with known contraindications
(or their clinicians) would usually not have to confront this
hypothetical question because prescribing the drug in the ﬁrst
place would contravene current medical knowledge. Therefore,
excluding patients with known contraindications places little
limits on generalizability.
In making a prescribing decision, physicians must assume
that patients will take a drug as directed. If clinicians knew
beforehand that a patient would not take a prescribed medica-
tion, they would not ponder the appropriateness of the drug in
the ﬁrst place. Consequently, excluding patients who are non-
adherent to their treatment independent of intolerance or treat-
ment failure—will not limit generalizability to the question raised
above. However, the situation is quite different if we restrict the
study population by disease severity, comorbidities, polyphar-
macy, and other risk factors for the study outcome. Data based
on such restrictions will limit physicians when making prescrib-
ing decisions concerning the excluded patient subgroups. The
obvious solution to this problem is to stratify analyses according
to relevant clinical subgroups, rather than restricting them out of
the analysis altogether, and then testing whether treatment effects
differ between groups [48]. The large size of health-care utiliza-
tion databases can allow performing such subgroup analyses
with substantial numbers of subjects, and represents an attractive
alternative to wholesale restriction.
Conclusion
Design of nonrandomized studies of comparative effectiveness
face several daunting issues, including measurement of exposure
and outcome challenged by biases in misclassiﬁcation and con-
founding. We identiﬁed a set of restrictions that analysts should
consider in studies of the effectiveness of therapies when using
large observational databases. Such restrictions will place few
limits on generalizability of research ﬁnding for most clinically
relevant treatment choices. Use of causal diagrams and restric-
tion are two techniques that can improve the theoretical basis for
analyzing treatment effects in study populations of more homo-
geneity, with reduced loss of generalizability.
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